Cargando…
The effects of aerobic, resistance, and combined exercises on the plasma irisin levels, HOMA-IR, and lipid profiles in women with metabolic syndrome: A randomized controlled trial
BACKGROUND/OBJECTIVE: Irisin is suggested to be an exercise beneficial effects mediator. This study aimed to examine the effects of the aerobic exercise (AE), resistance exercise (RE), and combined exercise (CE) on the plasma levels of irisin and some metabolic and anthropometric indices. METHODS: S...
Autores principales: | Dianatinasab, Aria, Koroni, Roghayeh, Bahramian, Mehrdad, Bagheri-Hosseinabadi, Zahra, Vaismoradi, Mojtaba, Fararouei, Mohammad, Amanat, Sasan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Society of Chinese Scholars on Exercise Physiology and Fitness
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334615/ https://www.ncbi.nlm.nih.gov/pubmed/32641925 http://dx.doi.org/10.1016/j.jesf.2020.06.004 |
Ejemplares similares
-
A Randomized Controlled Trial on the Effects of 12 Weeks of Aerobic, Resistance, and Combined Exercises Training on the Serum Levels of Nesfatin-1, Irisin-1 and HOMA-IR
por: Amanat, Sasan, et al.
Publicado: (2020) -
Response: The Effect of 12 Weeks Aerobic, Resistance, and Combined Exercises on Omentin-1 Levels and Insulin Resistance among Type 2 Diabetic Middle-Aged Women (Diabetes Metab J 2017;41:205-12)
por: Amanat, Sasan, et al.
Publicado: (2017) -
Corrigendum: Author's Name and Affiliation Correction. The Effect of 12 Weeks Aerobic, Resistance, and Combined Exercises on Omentin-1 Levels and Insulin Resistance among Type 2 Diabetic Middle-Aged Women
por: AminiLari, Zeinab, et al.
Publicado: (2017) -
The Effect of 12 Weeks Aerobic, Resistance, and Combined Exercises on Omentin-1 Levels and Insulin Resistance among Type 2 Diabetic Middle-Aged Women
por: AminiLari, Zeinab, et al.
Publicado: (2017) -
Are HOMA-IR and HOMA-B good predictors for diabetes and pre-diabetes subtypes?
por: Khalili, Davood, et al.
Publicado: (2023)